An idiot’s guide to lead optimisation for proteins
11–18 of 18 posts
Re: An idiot’s guide to lead optimisation for proteins
#12how many therapeutic proteins are there that aren't mabs or ~naturally occurring proteins (insulin, modified insulins, hirudin, cerezyme etc)? I can think of: etanercept
The largest commercial classes of multi-domain therapeutic proteins include the crispr (and similar) that drive gene therapies, and the chimeric antigen receptors (and similar) that drive cell therapies.
But lead optimization there look different than this page’s efforts.
Re: An idiot’s guide to lead optimisation for proteins
#13Re: An idiot’s guide to lead optimisation for proteins
#14how many therapeutic proteins are there that aren't mabs or ~naturally occurring proteins (insulin, modified insulins, hirudin, cerezyme etc)? I can think of: etanercept
A large and rapidly growing number. The largest commercial classes of multi-domain therapeutic proteins include the crispr (and similar) that drive gene therapies, and the chimeric antigen receptors (and similar) that drive cell therapies. But lead optimization there look different than this page’s efforts.
I guess I imagine one of the highest order obstacle to protein therapeutics to be immunogenicity, which is really hard to design around for a de Novo protein
Re: An idiot’s guide to lead optimisation for proteins
#15Anyone else read this as "An idiot's guide to Pb optimization for proteins," as in avoiding contaminated dietary protein isolates?
Re: An idiot’s guide to lead optimisation for proteins
#16Anyone else read this as "An idiot's guide to Pb optimization for proteins," as in avoiding contaminated dietary protein isolates?
Re: An idiot’s guide to lead optimisation for proteins
#17Anyone else read this as "An idiot's guide to Pb optimization for proteins," as in avoiding contaminated dietary protein isolates?
Re: An idiot’s guide to lead optimisation for proteins
#1820 different types coded for, but once you get into PTMs that number goes way up.